Skip to main content
. 2003 Jun;55(6):504–510. doi: 10.1046/j.1365-2125.2003.01788.x

Table 2.

Pulmonary function and capsaicin cough threshold on carbocysteine, ambroxol hydrochloride and placebo treatments in patients with stable bronchial asthma.

Control Placebo Carbocysteine Ambroxol hydrochloride
FVC as % pred. (%) 98.7 ± 8.0 94.0 ± 8.2 99.2 ± 7.3 97.1 ± 7.5
FEV1 as % pred. (%) 88.1 ± 7.5 86.0 ± 6.9 90.8 ± 6.5 88.8 ± 6.9
Cough threshold (κM)
Geometric mean 12.8 (5.5, 29.6) 11.0 (4.4, 27.5) 21.0 (8.8, 50.2)* 11.6 (5.8, 23.3)
Mean values of difference
Treatment regiments vs. control 0.86 (0.60, 1.23) 1.64 (1.01, 2.66) 0.91 (0.62, 1.32)
Mucoregulatory drugs vs. placebo 1.90 (1.05, 3.46) 1.05 (0.63, 1.76)
Carbocysteine vs. ambroxolhydrochloride 1.81 (1.06, 3.11)
Median 7.8 (3.9, 125.0) 7.8 (3.9, 31.2) 15.6 (3.9, 125.0) 7.8 (3.9, 62.5)
Mean values of difference
Treatment regiments vs. control 0.00 (−3.90, 62.5) 3.90 (0.00, 54.70) 0.00 (−31.25, 3.90)
Mucoregulatory drugs vs. placebo 3.90 (0.00, 29.30) 0.00 (−62.50, 11.70)
Carbocysteine vs. ambroxolhydrochloride 5.85 (0.00, 64.45)

Data are shown as standard error of the mean for FVC and FEV1, and as geometric mean value and median (95% CI) for capsaicin cough threshold, respectively.

*

P < 0.05 compared with placebo and ambroxol hydrochloride treatment respectively (Wilcoxon signed-ranks test data are transformed to logarithmic values for cough threshold).

If 95% CI does not include 1, showing significant difference between each group.

If 95% CI does not include 0, showing significant difference between each group.